Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Background: Anaplastic lymphoma kinase (ALK) plays a role in the development of lymphoma, lung cancer and neuroblastoma. While tyrosine kinase inhibitors (TKIs) have improved treatment outcomes, relapse remains a challenge due to on-target mutations and off-target resistance mechanisms. ALK-positive...

Full description

Saved in:
Bibliographic Details
Main Authors: Federica Malighetti, Matteo Villa, Mario Mauri, Simone Piane, Valentina Crippa, Ilaria Crespiatico, Federica Cocito, Elisa Bossi, Carolina Steidl, Ivan Civettini, Chiara Scollo, Daniele Ramazzotti, Carlo Gambacorti-Passerini, Rocco Piazza, Luca Mologni, Andrea Aroldi
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Biomedicines
Subjects:
ALK
macrophages
tumor immunology
CD47
TKIs (tyrosine kinase inhibitors)
neuroblastoma
Online Access:https://www.mdpi.com/2227-9059/12/12/2819
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/12/12/2819

Similar Items